Abstract:BACKGROUND:Conventional formulation of levofloxacin is rapidly and completely metabolized after administration. Fortunately, nanoparticle provides a new way to solve this problem. OBJECTIVE:To prepare a levofloxacin-loaded poly(lactic-co-glycolic acid) (PLGA) nanoparticle that can reduce administration frequency, maintain a stable and effective plasma concentration, and also can be combined with tissue-engineered scaffold materials. METHODS:Levofloxacin-loaded PLGA nanoparticles were prepared by emulsion solvent evaporation method. Twenty-four rabbits were taken to investigate the effect of nanoparticle formulation on the pharmacokinetics of levofloxacin and randomized into three groups (n=8 per group): general formulation group received an injection of levofloxacin (20 mg/kg)via ear vein; non-loaded nanoparticle group received an injection of blank nanoparticles; and levofloxaxin-loaded nanoparticle group received an injection of the corresponding levofloxacin-loaded nanoparticles. At different times, blood samples were collected to analyze the drug concentration of levofloxaxin. The antimicrobial activity of the levofloxacin-loaded nanoparticle was evaluated based on the rabbit model of Escherichia coli-induced urinary tract infection. Forty-five New Zealand white rabbits were used to establish urinary tract infection models and randomly divided into three groups (n=15 per group). In negative control group, rabbits received only an injection of normal salinevia ear vein. In conventional formulation group, rabbits received an injection of levofloxacin (20 mg/kg). In nanoparticle group, rabbits received an injection of the corresponding levofloxacin nanoparticles. Subsequently, blood samples were obtained, and white blood cell (WBC) count and neutrophil percentage was tested; at the same time, the middle segment morning urine was collected to detect bacteriuria and urine WBC positive rates. At 9 days, the histopathologic analysis of the bladder mucosa was done. RESULTS AND CONCLUSION:(1)In vivo the pharmacokinetics: Compared with the conventional formulation group, the ideal levofloxacin-loaded PLGA nanoparticles prepared under optimal conditions significantly reduced the fluctuations in plasma concentration and frequency of administration. (2) Antimicrobial activity:Escherichia coli-induced urinary tract infection was gradualy in control in the conventional formulation group and levofloxacin-loaded PLGA nanoparticle group, and basically cured at 9 days after injection. In addition, the number of cured patients was basically higher in the levofloxacin-loaded PLGA nanoparticle group than the conventional formulation group at the same time point, but there was a significant difference between the two groups only at 5 days after treatment. It can be concluded that levofloxacin-PLGA nanoparticles provide a well-sustained delivery system for treatment or prevention of urinary tract infections and provide a foundation for further investigations on tissue-engineered urethral reconstruction.

In Vitro and in Vivo Evaluation of Levofloxacin Sustained-Release Capsules.

In vitro and in vivo evaluation of ofloxacin sustained release pellets

Dissolution in vitro and pharmacokinetics of levofloxacin hydrochloride sustained-release tablets

Evaluation of Levofloxacin Release Characteristics from a Human Foldable Capsular Vitreous Body in Vitro.

Gastro-floating tablets of cephalexin: preparation and in vitro/in vivo evaluation.

Evaluation of the Levofloxacin Release Characters from A Rabbit Foldable Capsular Vitreous Body

Preparation and Physicochemical Characterization of Levofloxacin-Loaded Poly(lactic-Co-glycolic Acid) Nanoparticles

Preparation, releasing feature and local biological safety evaluation of bone implanted sustained-releasing levofloxacin tablets

In Vitro and in Vivo Evaluation of an in Situ Forming Gel System for Sustained Delivery of Florfenicol

Preparation and in Vitro Release Study of Sustained-release Coated Pellets Containing Clarithromycin

Preparation of Cefalexin Sustained-release Pellets and Investigation on Its Drug Release in Vitro

Targeted delivery of levofloxacin-liposomes for the treatment of pulmonary inflammation.

Preparation and in Vitro Releasing Performance of Intraocular Polylactide-Levofloxacin Sustained Release Implants

Floating Tablets for Controlled Release of Ofloxacin Via Compression Coating of Hydroxypropyl Cellulose Combined with Effervescent Agent

Studies on Preparation and in vitro Release of Levodropropizine Modified-release Capsules

Optimization of Levofloxacin Hydrochloride Sustained-release Tablets by Central Composite Design

Study on Encapsulation Efficiency and In vitro Release Profile of Levofloxacin Hydrochloride Liposome

Preparation and in Vitro/in Vivo Evaluation of Bezafibrate Sustained-Release Pellet Capsules

Prolonged systemic delivery of antibacterial agent levofloxacin using liposomes

Controlled Release Bilayer Floating Effervescent and Noneffervescent Tablets Containing Levofloxacin and Famotidine

Development and characterization of gastro-floating sustained-release capsule with improved bioavailability of levodopa